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Abstract—Synthesis of some novel aminocyclopentitol analogues has been achieved through a functionally embellished cyclopen-
tanoid derivative of well-defined stereochemical disposition, obtained via a Grob-type fragmentation sequence executed within the
norbornyl framework. The glycosidase inhibition studies of the new aminocyclopentitols indicate them to be weak inhibitors.
Recent years have witnessed a great deal of interest in
the synthesis of polyhydroxylated aminocyclopentanes
(aminocyclopentitols), which either exist as such in
nature or constitute important sub-structures among
several complex natural products, and display a wide
range of biological activity profiles.1 Among the well
known examples of this class of molecules of contempor-
ary interest are glycosidase inhibitors mannostatin A
1, trehazolin 2 and their synthetic analogues such as
Merrel Dow’s cyclopentylamine 3 and recently dis-
closed aminocyclopentitols 4a and 4b, and carbocyclic
nucleosides such as neplanocin A 5, aristeromycin 6
and their analogues.1–3 In the context of glycosidase
inhibition, these compounds can be considered as struc-
tural analogues of carbohydrates containing a basic
nitrogen function at the anomeric center in the proton-
ated form. Generally, their mode of action is presumed
to proceed via mimicking of the glycopyranosyl cation
in the transition state of the glycosidase catalyzed reac-
tion.4 Besides 1–6, several aminocyclopentitol based
glycosidase inhibitors, having gluco-, manno-, galacto-
and fuco-stereochemical patterns have been synthesized
and evaluated against their corresponding glycosidases
in the recent past.1–3 However, glycosidase inhibition by
aminocyclopentitols as a function of their structural
and stereochemical features still remains to be fully
understood2b–f and, therefore, the synthesis of newer
analogues could provide not only a better understand-
ing of glycosidase functioning but also lead to more
active inhibitors, which can be used for the treatment of
carbohydrate metabolism related disorders.4
In connection with our ongoing project on the synthesis
of carbasugars and azasugars,5 we have recently dis-
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Scheme 1.
closed a stereoselective synthesis of the densely func-
tionalized cyclopentanoid framework 9 through further
elaboration of the cyclopentene ester 8, obtained in a
Grob-type fragmentation sequence orchestrated within
the norbornyl framework 7, Scheme 1.5c Herein, we
report the transformation of cyclopentanoid framework
9 to new aminocyclopentitols having the altrose
configuration and to an analogue of the carbocyclic
nucleoside neplanocin A, in which the amino and
hydroxy functionalities are transposed, and evaluate
their glycosidase inhibition activity.
The free hydroxy group in 9 was first activated as a
leaving group in the form of the mesylate functionality
and then the iodide was subjected to reductive dehalo-
genation with NaBH3CN to furnish the methyl com-
pound 106 (Scheme 2). In order to set up the requisite
amine functionality, the mesylate group in 10 was dis-
placed using NaN3 as a nucleophile to afford 11.6
Catalytic hydrogenation of the azide group in 11 pro-
vided an access to the free amine, which was purified
and characterized as its acetamide derivative 12.6 Acid
catalyzed deprotection of the amide as well as the
acetonide group in 12 was effected smoothly to furnish
the desired amine, a stereoisomer of the potent
inhibitor 4b,2f as its hydrochloride salt 136 (Scheme 2).
In a related sequence, the mesylate 14 derived from 9
on peracid mediated oxidation of the iodomethyl func-
tionality was directly transformed to the hydroxy com-
pound 15.6 Alternately, 15 could also be accessed from
14 via dehydroiodination to the exocyclic olefin and
hydroboration–oxidation. However, the yield and
stereoselectivity in this sequence was rather modest.
Further, the mesylate group in 15 was smoothly dis-
placed by the azide anion to yield 16, which was further
transformed to 17,6 closely related to the powerful
inhibitor 4a,2e in a two-step sequence involving azide
group reduction and acid catalyzed deprotection of the
acetonide moiety see (Scheme 2).
Syntheses of novel amino cyclopentitols with an amino
group in the side-chain and the carbocyclic nucleoside
analogue of neplanocin A 5 in which the purine and
hydroxy group positions on the cyclopentitol moiety
are swapped was attempted next as outlined in Scheme
3. Sodium azide mediated displacement of the
iodomethyl group and concomitant elimination of the
mesylate group in 14 led directly to 18 with the requi-
site disposition of the double bond (cf. 5). Reduction of
the azide group in 18 under carefully crafted conditions
generated the aminomethyl derivative 19,6 which upon
deprotection of the acetonide protective group yielded
the novel cyclopentitol with a primary amino group 20,
as its hydrochloride salt. In a related sequence, sodium
acetate mediated displacement of the iodo functionality
and concomitant elimination of the mesylate group in
14 furnished 21, which upon alkaline hydrolysis pro-
vided access to 22.6 To transform 22 into the carbo-
cyclic nucleoside analogue, the adenine moiety was
attached to it under Mitsunobu conditions in a regiose-
Scheme 2. Reagents and conditions : (a) MsCl, Et3N, DCM −10 to 0°C, 92% (b) NaBH3CN, HMPA, 100°C, 1 h, 55%; (c) NaN3,
DMF, 60°C, 2 h, 67%; (d) Lindlar’s catalyst, H2, EtOH, 1 h; Ac2O, DMAP, DCM, 45 min, 82% for two-steps; (e) 5% HCl,
Et2O–H2O (1:9), 70°C, >90%; (f) MCPBA, DCM, 0°C, 5 h, 76%; (g) DBU, CH3CN, overnight, 92%; BH3·THF, −10 to rt,
overnight, then 30% H2O2, 3 M NaOH, 0°C, 2 h, 58%; (h) same as (c), 78%; (i) Lindlar’s catalyst, H2, EtOH, 2 h; 5% HCl,
Et2O–H2O (1:4), >90%.
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Scheme 3. Reagents and conditions : (a) NaN3, DMF, 60°C, 2 h, 67%; (b) PPh3, aq. NH3–Py (1:1), overnight, 93%; (c) 5% HCl,
Et2O–H2O (1:9), rt, >90%; (d) NaOAc, DMF, 100°C, 2 h, 77%; (e) KOH, MeOH, rt, 2 h, 68%; (f) DEAD, adenine, 1,4-dioxan,
rt, 36 h, 83%; (g) same as (c), quant.
lective manner to deliver 23.6 Acid catalyzed deprotec-
tion of the acetonide moiety in 23 led directly to the
formation of 24.6 The 1H and 13 C NMR spectra of
both 23 and 24 clearly indicated the N9 substituted
structures rather than the N7 substituted structures7. It
is to be noted that structural analogues of carbocyclic
nucleosides have evoked a great deal of attention1b as
anti-viral and anti-HIV agents and to our knowledge 24
represents a new variation.
Glycosidase inhibitory activity of aminocyclopentitol
derivatives 13 and 17 having the altrose configuration,
and of the carbocyclic nucleoside analogue 24 and the
related aminocyclopentene derivative 20 was evaluated
against -glucosidase (yeast), -glucosidase (sweet
almond), -galactosidase (green coffee beans) and -
galactosidase (E. coli ) using their corresponding ortho-
or para-nitrophenyl-glycopyranosides as substrates at
optimum pH and temperature of each enzyme. While
the methyl derivative 13 was found to be a weak
anomer selective and competitive inhibitor of -gluco-
sidase (Ki=503 M), the hydroxymethyl derivative 17
turned out to be an even weaker inhibitor with only
13% inhibition at 1 mM concentration. Methyl substi-
tuted aminocyclopentitol 13 showed a non-selective
inhibition against - and -galctosidases with 30 and
40% inhibition, respectively, at 1 mM concentration
whereas there was no observable inhibition by 17 in the
case of other glycosidases. This marked decrease in the
inhibitory activity of 13 and 17, as compared with the
closely related diastereomeric aminocyclopentitols
reported recently (cf. 4a,b),2b–e could be attributed to
the mismatch of configuration with the transition-state
of corresponding enzymes. The carbocyclic nucleoside
analogue 24 and the related aminocyclopentene 20 did
not show any glycosidase inhibition against the
enzymes studied by us, underscoring the need for a
wider screen.
In conclusion, we have demonstrated the versatility of
readily available cyclopentanoid derivative 95c in
stereospecific synthesis of two new aminocyclopentitols
13 and 17 with previously unknown stereochemical
dispositions. A novel carbocyclic nucleoside analogue
24 of neplanocin A is also reported. While 13 was
found to be a weak anomer selective inhibitor of -glu-
cosidase, the other cyclopentitols 17, 20, 24 were inef-
fective as glycosidase inhibitors.
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